Movement Disorder Program At Global Neuroscience Institute News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
- FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., April 20, 2021 /PRNewswire/ While this past year living in quarantine during the pandemic did not just create economical damage, and social disruption… it could have also increased new cases of secondary medical results from the pandemic. According to various reports the outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research study by Katya Numbers et al., published in Nature Reviews Neurology, in January 2021, the population with dementia are at high risk of contracting COVID-19 infection as the cognitive symptoms cause difficulty to abide by the safety guidelines that were proposed to contain the viral spread. Furthermore, older populations with dementia are also more likely to have more severe disease consequences than those without dementia. Additionally, the statem ....

United States , United Kingdom , Charles Strongo , Kostenloser Wertpapierhandel , Carmen Castrillo Viguera , Movement Disorder Program At Global Neuroscience Institute , Fn Media Group , Anavex Life Sciences Corp , Quidel Corporation , Parkinson Movement Disorder Alliance , Adamas Pharmaceuticals Inc , Global Wholehealth Partners Corp , Drug Administration , Office For National Statistics United Kingdom , Adamas Pharmaceuticals , Exchange Commission , Alzheimer Disease International , Clinical Laboratory Improvement Amendments , Securities Exchange , American Academy Of Neurology , Clinical Development At Biogen , Katya Numbers , Nature Reviews Neurology , National Statistics United Kingdom , Mordor Intelligence , Anavex Life Sciences ,